DE60210402T2 - System zur Abgabe einer Tobramycin-Formulierung - Google Patents
System zur Abgabe einer Tobramycin-Formulierung Download PDFInfo
- Publication number
- DE60210402T2 DE60210402T2 DE60210402T DE60210402T DE60210402T2 DE 60210402 T2 DE60210402 T2 DE 60210402T2 DE 60210402 T DE60210402 T DE 60210402T DE 60210402 T DE60210402 T DE 60210402T DE 60210402 T2 DE60210402 T2 DE 60210402T2
- Authority
- DE
- Germany
- Prior art keywords
- tobi
- tobramycin
- dose
- treatment
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 title claims abstract description 583
- 229960000707 tobramycin Drugs 0.000 title claims abstract description 266
- 238000009472 formulation Methods 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 239000000443 aerosol Substances 0.000 claims abstract description 130
- 208000015181 infectious disease Diseases 0.000 claims abstract description 16
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 37
- 208000032536 Pseudomonas Infections Diseases 0.000 claims 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 abstract description 10
- 229940126574 aminoglycoside antibiotic Drugs 0.000 abstract description 8
- 229940035289 tobi Drugs 0.000 description 318
- 238000011282 treatment Methods 0.000 description 222
- 102100032341 PCNA-interacting partner Human genes 0.000 description 129
- 101710196737 PCNA-interacting partner Proteins 0.000 description 129
- 210000002966 serum Anatomy 0.000 description 104
- 206010036790 Productive cough Diseases 0.000 description 91
- 210000003802 sputum Anatomy 0.000 description 91
- 208000024794 sputum Diseases 0.000 description 91
- 210000004072 lung Anatomy 0.000 description 64
- 210000002700 urine Anatomy 0.000 description 57
- 208000009079 Bronchial Spasm Diseases 0.000 description 48
- 239000006199 nebulizer Substances 0.000 description 48
- 208000014181 Bronchial disease Diseases 0.000 description 47
- 206010006482 Bronchospasm Diseases 0.000 description 47
- 229940079593 drug Drugs 0.000 description 40
- 239000003814 drug Substances 0.000 description 40
- 238000000151 deposition Methods 0.000 description 39
- 230000008021 deposition Effects 0.000 description 38
- 239000000243 solution Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- 238000004544 sputter deposition Methods 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 230000003115 biocidal effect Effects 0.000 description 25
- 230000008859 change Effects 0.000 description 22
- 238000012216 screening Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 230000002093 peripheral effect Effects 0.000 description 15
- 230000004199 lung function Effects 0.000 description 11
- 210000003300 oropharynx Anatomy 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000002411 adverse Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000008030 elimination Effects 0.000 description 9
- 238000003379 elimination reaction Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 101150034459 Parpbp gene Proteins 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 230000002285 radioactive effect Effects 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 230000000241 respiratory effect Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 7
- 229940126575 aminoglycoside Drugs 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000003238 esophagus Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 208000019693 Lung disease Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000000889 atomisation Methods 0.000 description 5
- 229940124630 bronchodilator Drugs 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009533 lab test Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000013125 spirometry Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 241001227713 Chiron Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- 240000003517 Elaeocarpus dentatus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 241000187178 Streptoalloteichus tenebrarius Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- DNNSSWSSYDEUBZ-OIOBTWANSA-N krypton (81mKr) gas Chemical compound [81Kr] DNNSSWSSYDEUBZ-OIOBTWANSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940033872 namenda Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940101667 tobramycin 60 mg/ml Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29223401P | 2001-05-18 | 2001-05-18 | |
| US292234P | 2001-05-18 | ||
| PCT/US2002/015999 WO2002094217A1 (en) | 2001-05-18 | 2002-05-17 | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60210402D1 DE60210402D1 (de) | 2006-05-18 |
| DE60210402T2 true DE60210402T2 (de) | 2006-12-07 |
Family
ID=23123791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60210402T Revoked DE60210402T2 (de) | 2001-05-18 | 2002-05-17 | System zur Abgabe einer Tobramycin-Formulierung |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US20030143162A1 (enExample) |
| EP (2) | EP2186508A3 (enExample) |
| JP (2) | JP2004534763A (enExample) |
| AT (1) | ATE322249T1 (enExample) |
| AU (1) | AU2010210026A1 (enExample) |
| CA (1) | CA2447600C (enExample) |
| DE (1) | DE60210402T2 (enExample) |
| DK (1) | DK1320355T3 (enExample) |
| ES (1) | ES2261735T3 (enExample) |
| PT (1) | PT1320355E (enExample) |
| WO (1) | WO2002094217A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW465235B (en) | 1998-09-17 | 2001-11-21 | United Video Properties Inc | Electronic program guide with digital storage |
| PT1320355E (pt) * | 2001-05-18 | 2006-08-31 | Chiron Corp | Sistema para administracao de uma formulacao de tobramicina |
| US20040022740A1 (en) * | 2001-07-10 | 2004-02-05 | Baker William R. | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
| WO2003053411A1 (en) | 2001-12-19 | 2003-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
| US7334580B2 (en) * | 2002-05-07 | 2008-02-26 | Smaldone Gerald C | Methods, devices and formulations for targeted endobronchial therapy |
| US7607436B2 (en) * | 2002-05-06 | 2009-10-27 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
| EP1545459A4 (en) * | 2002-08-02 | 2007-08-22 | Transave Inc | PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME |
| US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
| AU2002953095A0 (en) * | 2002-11-29 | 2002-12-19 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| CA2529817C (en) | 2003-03-10 | 2013-02-12 | Optimer Pharmaceuticals, Inc. | Novel antibacterial agents |
| ATE350024T1 (de) * | 2003-10-15 | 2007-01-15 | Pari Gmbh | Flüssige zubereitung enthaltend tobramycin |
| WO2005089448A2 (en) * | 2004-03-18 | 2005-09-29 | Transave, Inc. | Administration of cisplatin by inhalation |
| US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
| ATE493969T1 (de) * | 2004-05-17 | 2011-01-15 | Corus Pharma Inc | Kombination aus fosfomycin/aminoglycosid in aerosolform zur behandlung bakterieller atemwegsinfektionen |
| AU2005245018A1 (en) * | 2004-05-21 | 2005-12-01 | Transave, Inc. | Treatment of lung diseases and pre-lung disease conditions |
| PL1765288T3 (pl) | 2004-06-18 | 2013-04-30 | Novartis Ag | Preparaty tobramycyny do leczenia zakażań oskrzeli |
| WO2006055352A2 (en) * | 2004-11-08 | 2006-05-26 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
| US9205050B2 (en) * | 2005-09-29 | 2015-12-08 | Bayer Intellectual Property Gmbh | Antibiotic formulations, unit doses, kits and methods |
| AU2013206401B2 (en) * | 2005-09-29 | 2016-06-23 | Novartis Ag | Antibiotic formulations, unit doses, kits, and methods |
| US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| US20070190180A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
| WO2007056236A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
| WO2007064658A2 (en) * | 2005-11-30 | 2007-06-07 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
| AU2006322076C1 (en) | 2005-12-08 | 2013-11-14 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| WO2007070875A1 (en) * | 2005-12-15 | 2007-06-21 | Aerosol Science Laboratories, Inc. | Treatment of active infections and related compositions |
| JP2008199905A (ja) * | 2007-02-16 | 2008-09-04 | Snow Brand Milk Prod Co Ltd | 乳酸菌生残性向上剤 |
| AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| CN101981688B (zh) * | 2008-04-02 | 2014-04-02 | Imec公司 | 制造半导体器件的方法以及半导体器件 |
| WO2010048600A1 (en) * | 2008-10-24 | 2010-04-29 | Cempra Pharmaceuticals, Inc. | Methods for treating resistant diseases using triazole containing macrolides |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| US9480679B2 (en) | 2009-09-10 | 2016-11-01 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and MAC diseases |
| HRP20160168T1 (hr) | 2010-03-22 | 2016-03-25 | Cempra Pharmaceuticals Inc | Kristalne forme makrolida i njihova uporaba |
| EP2571506B1 (en) | 2010-05-20 | 2017-05-10 | Cempra Pharmaceuticals, Inc. | Processes for preparing macrolides and ketolides and intermediates therefor |
| WO2012007130A1 (en) * | 2010-07-12 | 2012-01-19 | Xellia Pharmaceuticals Aps | Treatment of lung infections by administration of tobramycin by aerolisation |
| KR20130120458A (ko) | 2010-09-10 | 2013-11-04 | 셈프라 파마슈티컬스, 인크. | 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드 |
| BR112014000275A2 (pt) | 2011-07-12 | 2017-04-18 | Cardeas Pharma Inc | formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat) |
| US8826904B2 (en) | 2011-07-12 | 2014-09-09 | Cardeas Pharma Corporation | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis |
| WO2013148891A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| GB201208080D0 (en) | 2012-05-09 | 2012-06-20 | Norton Healthcare Ltd | Tobramycin formulation |
| EP2892524B1 (en) | 2012-09-04 | 2020-11-25 | Eleison Pharmaceuticals, LLC | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
| ES2743039T3 (es) | 2012-11-29 | 2020-02-18 | Insmed Inc | Formulaciones de vancomicina estabilizada |
| UA117673C2 (uk) | 2013-01-11 | 2018-09-10 | Кселлія Фармасьютікалз Апс | Поліміксини, композиція, спосіб одержання і спосіб застосування (варіанти) |
| EP2968801B1 (en) | 2013-03-14 | 2018-09-26 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| MX356772B (es) | 2013-03-15 | 2018-06-13 | Cempra Pharmaceuticals Inc | Procesos convergentes para la preparacion de agentes antibacterianos macrolidos. |
| EP3466432B1 (en) | 2014-05-15 | 2020-07-08 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| EA201692569A1 (ru) | 2014-07-09 | 2017-05-31 | Кселлия Фармасьютикалз Апс | Полимиксины с низкой степенью замещения и композиции, их содержащие |
| ES2721401T3 (es) | 2014-10-03 | 2019-07-31 | Xellia Pharmaceuticals Aps | Dispositivo de inhalación |
| WO2016050928A1 (en) | 2014-10-03 | 2016-04-07 | Xellia Pharmaceuticals Aps | Compositions |
| US10617703B2 (en) | 2014-12-10 | 2020-04-14 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11278590B2 (en) | 2015-08-05 | 2022-03-22 | Cmpd Licensing, Llc | Compositions and methods for treating nail infections |
| US11446236B2 (en) | 2015-08-05 | 2022-09-20 | Cmpd Licensing, Llc | Topical antimicrobial compositions and methods of formulating the same |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US10898455B2 (en) | 2016-01-07 | 2021-01-26 | Cmpd Licensing, Llc | Urea cream formulations |
| US10898491B2 (en) | 2015-12-18 | 2021-01-26 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11690815B2 (en) | 2015-08-05 | 2023-07-04 | Cmpd Licensing Llc | Hyperkeratotic skin condition treatments and compositions |
| US10525025B2 (en) | 2016-11-17 | 2020-01-07 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US9999604B2 (en) | 2016-11-17 | 2018-06-19 | Cmpd Licensing, Llc | Compounded solutions of diclofenac and lidocaine and methods |
| WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| WO2020163416A1 (en) * | 2019-02-05 | 2020-08-13 | Mylan Inc | Devices and methods for tobramycin inhalation treatment |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993223A (en) | 1974-07-25 | 1976-11-23 | American Home Products Corporation | Dispensing container |
| US4502616A (en) | 1982-01-04 | 1985-03-05 | Health Care Concepts, Inc. | Single use vial |
| GB8801655D0 (en) | 1988-01-26 | 1988-02-24 | Waverley Pharma Ltd | Ampoules |
| EP0326529B1 (en) | 1988-01-28 | 1992-12-30 | Lameplast S.R.L. | A strip of phials for pharmaceuticals, cosmetics and other products |
| GB8802349D0 (en) | 1988-02-03 | 1988-03-02 | Waverley Pharma Ltd | Ampoule with luer |
| DE3916840A1 (de) | 1988-09-21 | 1990-03-29 | Bernd Hansen | Ampulle |
| US5409125A (en) | 1989-12-11 | 1995-04-25 | Aktiebolaget Astra | Unit dose container |
| CA2027690A1 (en) | 1990-10-18 | 1992-04-19 | Christian Laing | Plastic ampul |
| FR2687066A1 (fr) | 1992-02-06 | 1993-08-13 | Oreal | Ampoule autocassable. |
| US5508269A (en) * | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US5758637A (en) * | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
| US6083922A (en) * | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| SI20959A (sl) * | 1998-12-17 | 2003-02-28 | Pathogenesis Corporation | Metoda za zdravljenje hudega kroničnega bronhitisa (bronhiektazije) z aerosoliziranimi antibiotiki |
| SE9902627D0 (sv) * | 1999-07-08 | 1999-07-08 | Siemens Elema Ab | Medical nebulizer |
| DE19953317C1 (de) | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
| PT1320355E (pt) | 2001-05-18 | 2006-08-31 | Chiron Corp | Sistema para administracao de uma formulacao de tobramicina |
-
2002
- 2002-05-17 PT PT02771857T patent/PT1320355E/pt unknown
- 2002-05-17 DK DK02771857T patent/DK1320355T3/da active
- 2002-05-17 ES ES02771857T patent/ES2261735T3/es not_active Expired - Lifetime
- 2002-05-17 JP JP2002590936A patent/JP2004534763A/ja active Pending
- 2002-05-17 EP EP09015943A patent/EP2186508A3/en not_active Withdrawn
- 2002-05-17 CA CA2447600A patent/CA2447600C/en not_active Expired - Fee Related
- 2002-05-17 WO PCT/US2002/015999 patent/WO2002094217A1/en not_active Ceased
- 2002-05-17 US US10/151,701 patent/US20030143162A1/en not_active Abandoned
- 2002-05-17 DE DE60210402T patent/DE60210402T2/de not_active Revoked
- 2002-05-17 AT AT02771857T patent/ATE322249T1/de active
- 2002-05-17 EP EP02771857A patent/EP1320355B1/en not_active Revoked
-
2003
- 2003-12-22 US US10/743,529 patent/US6890907B2/en not_active Expired - Lifetime
-
2004
- 2004-07-01 US US10/883,143 patent/US20040265241A1/en not_active Abandoned
-
2005
- 2005-05-10 US US11/125,670 patent/US20050207987A1/en not_active Abandoned
- 2005-05-10 US US11/126,108 patent/US20050201947A1/en not_active Abandoned
-
2007
- 2007-10-24 US US11/923,486 patent/US7825095B2/en not_active Expired - Lifetime
-
2009
- 2009-08-07 JP JP2009185305A patent/JP2009269923A/ja active Pending
-
2010
- 2010-08-09 AU AU2010210026A patent/AU2010210026A1/en not_active Abandoned
- 2010-09-17 US US12/884,505 patent/US20110005518A1/en not_active Abandoned
-
2011
- 2011-11-14 US US13/295,228 patent/US8507454B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2447600C (en) | 2015-10-20 |
| AU2010210026A1 (en) | 2010-09-02 |
| US20080095717A1 (en) | 2008-04-24 |
| DE60210402D1 (de) | 2006-05-18 |
| EP1320355B1 (en) | 2006-04-05 |
| PT1320355E (pt) | 2006-08-31 |
| US20050207987A1 (en) | 2005-09-22 |
| EP1320355A1 (en) | 2003-06-25 |
| US8507454B2 (en) | 2013-08-13 |
| JP2004534763A (ja) | 2004-11-18 |
| US20050201947A1 (en) | 2005-09-15 |
| EP2186508A2 (en) | 2010-05-19 |
| ATE322249T1 (de) | 2006-04-15 |
| US7825095B2 (en) | 2010-11-02 |
| US20110005518A1 (en) | 2011-01-13 |
| DK1320355T3 (da) | 2006-07-31 |
| CA2447600A1 (en) | 2002-11-28 |
| JP2009269923A (ja) | 2009-11-19 |
| ES2261735T3 (es) | 2006-11-16 |
| US20120101055A1 (en) | 2012-04-26 |
| US20040265241A1 (en) | 2004-12-30 |
| US6890907B2 (en) | 2005-05-10 |
| US20040131555A1 (en) | 2004-07-08 |
| WO2002094217A1 (en) | 2002-11-28 |
| US20030143162A1 (en) | 2003-07-31 |
| EP2186508A3 (en) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60210402T2 (de) | System zur Abgabe einer Tobramycin-Formulierung | |
| DE69511374T2 (de) | Neue und verbesserte aminoglykosidformulierung als aerosol | |
| DE69737510T2 (de) | Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation | |
| DE60103527T2 (de) | Optimierte Tobramycin-Formulierung zur Aerosolbildung | |
| AU710821B2 (en) | Fluticasone propionate formulations | |
| DE69018092T2 (de) | Aerosolzubereitung von glutathion und verfahren zur erhöhung des glutathionspiegels in der lunge. | |
| DE69925849T2 (de) | Verabreichung von einem aerosolisierten wirkstoff unter moduliertem strömungswiderstand | |
| DE69133584T4 (de) | Vorrichtung zum Behandeln einen Lungengefässverengung und von Asthma | |
| DE69429832T2 (de) | Verfahren zur behandlung von festhaltenden lungensekreten | |
| DE69631159T3 (de) | Pulver und deren verwendung in trockenpulverinhalatoren | |
| DE69526425T2 (de) | Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen | |
| DE69218329T2 (de) | Verabreichungsverfahren von Dipalmitoylphosphatidylcholindispersionen | |
| CH693763A5 (de) | Verwendung eines Antibiotikums zur Herstellung eines Medikamentes zur Behandlung von schwerer chronischer Bronchitis (Bronchiektase). | |
| CN106074461A (zh) | 通过氨基糖苷气雾给药治疗肺部感染 | |
| DE69724991T2 (de) | Behandlung von bronchitis mit diuridintretraphosphat | |
| AU2016202597A1 (en) | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration | |
| KR20010033310A (ko) | 우리딘 삼인산염의 신규한 제약학적 조성물 | |
| EP1673074A2 (de) | Flüssige zubereitung enthaltend tobramycin | |
| US4908382A (en) | Method for treating asthma | |
| DE69722610T2 (de) | Neue Inhalationspräparate enthaltend CR 2039 (Andolast) | |
| O'RIORDAN et al. | Production of an aerosol of cyclosporine as a prelude to clinical studies | |
| DE69917658T2 (de) | Micronisierte pharmazeutische zusammensetzungen | |
| DE60022070T2 (de) | Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen | |
| DE60202299T2 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
| EP1598059A1 (en) | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US |
|
| 8331 | Complete revocation |